Table 1 Demographics of the training and validation study populations
| Â | Training | Validation | ||
|---|---|---|---|---|
Control (n = 186) | NSCLC (n = 95) | CXR finding: nodule | ||
Control (n = 119) | Lung cancer (n = 119) | |||
Gender | ||||
 Male | 107 | 34 | 69 | 69 |
 Female | 79 | 61 | 50 | 50 |
Age (years) | ||||
 Mean (SD) | 62.3 (11.8) | 66.5 (9.6) | 63.7 (5.2) | 64.4 (5.3) |
Smoking | ||||
 Ever smokers | 186 | 95 | 106 | 106 |
 Never smokers | – | – | 13 | 13 |
 Pack years, mean (SD) | 37.4 (21.5) | 44.5 (21.3) | 46.0 (32.4) | 55.3 (40.9) |
Abnormal suspicious finding | ||||
 Nodule | NA | NA | 119 | 119 |
Stage | ||||
 I |  | 95 (100%) |  | 5 (4.2%) |
 Ia |  | – |  | 51 (42.9%) |
 Ib |  | – |  | 15 (12.6%) |
 II |  | – |  | 10 (8.4%) |
 III |  | – |  | 19 (16.0%) |
 IV |  | – |  | 14 (11.8%) |
 NA |  | – |  | 5 (4.2%) |
Histology | ||||
 Adenocarcinoma |  | 63 (66.3%) |  | 57 (47.9%) |
 BAC |  | 4 (4.2%) |  | 20 (16.8%) |
 Squamous cell |  | 15 (15.8%) |  | 25 (21.0%) |
 Large cell |  | 6 (6.3%) |  | 4 (3.4%) |
 NSCLC |  | 4 (4.2%) |  | 2 (1.7%) |
 Neuroendocrine |  | 2 (2.1%) |  | 2 (1.7%) |
 Small cell |  | – |  | 5 (4.2%) |
 Adenosquamous |  | 1 (1.1%) |  | 4 (3.4%) |